Metagenomi Therapeutics, Inc. (MGX) stock
Close on Nov 16, 2026Market cap $25.69MP/E –Yield –
Metagenomi Therapeutics, Inc. saw revenue fall 51.8% to $25.21M over fiscal 2025. Free cash flow was -$85.80M. At the latest close the market valued the company at $25.69M.
Key statistics
Valuation at the latest close; fundamentals over fiscal 2025, balances at Jun 30, 2026
Valuation
- Market cap
- $25.69M
- P/E ratio
- –
- Price to sales
- –
- Price to book
- 0.23
- Dividend yield
- –
- Free cash flow yield
- -333.99%
Fundamentals
- Revenue
- $25.21M
- Net income
- -$93.46M
- EPS, diluted
- -$2.49
- Free cash flow
- -$85.80M
- Book value per share
- $2.99
- Diluted shares
- 38M
Trading
- Next earnings
- Mar 4, 2027 (estimated, during market hours)
- Previous close
- $0.69
- Open
- $0.70
- Day's range
- $0.66 – $0.71
- Volume
- 193,181
- Average volume (20 days)
- 162,160
- 52-week range
- $0.60 – $1.87
- RSI (14 days)
- 32.3
- Volatility (1 year)
- 52.7%
- Relative volume
- 1.19×
Market cap history
Month-end market cap since 2024, using shares outstanding reported at the time
Total return vs. the S&P 500
Price change plus reinvested dividends, to the close on Nov 16, 2026. The S&P 500 is measured by the SPY fund.
| Period | MGX | S&P 500 | Difference | MGX per year | S&P 500 per year |
|---|---|---|---|---|---|
| 1 month | -13.3% | -3.1% | −10.2 pts | ||
| 3 months | -44.7% | -4.5% | −40.3 pts | ||
| Year to date | -58.0% | +9.4% | −67.4 pts | ||
| 1 year | -60.9% | +11.3% | −72.2 pts |
Four years at a glance
Fiscal years 2022 to 2025 and trailing twelve months, USD
Revenue
Operating income
Net income
EPS, diluted
Free cash flow
Press releases
Releases Metagenomi Therapeutics filed with the SEC as exhibits to Form 8-K or 6-K
- Results
- Update
- Results
- Results
- Results
- Results
About Metagenomi Therapeutics
Biological Products, (No Diagnostic Substances)
Metagenomi Therapeutics, Inc. is a genetic medicines company that develops next-generation genome editing systems to create curative therapies for patients. The company focuses on research and development efforts in genome editing using programmable nucleases, base editing, and RNA- and DNA-mediated integration systems, which include prime editors and CRISPR-associated transposases. It has not yet commercialized any product candidates and conducts research and development activities through strategic collaborations and license agreements with pharmaceutical partners such as Ionis and Moderna.
Company profile, executives and historyMetagenomi Therapeutics stock: common questions
What is Metagenomi Therapeutics's stock price?
MGX closed at $0.68 on Nov 16, 2026, down 1.69% on the day. Over the past 52 weeks it traded between $0.60 and $1.87.
What is Metagenomi Therapeutics's market cap?
Metagenomi Therapeutics was worth $25.69M at the close on Nov 16, 2026: the share price times the diluted shares outstanding.
What is MGX's P/E ratio?
Metagenomi Therapeutics lost money over the twelve months to Jun 30, 2026 (diluted EPS -$2.49), so it has no meaningful P/E ratio.
How much revenue does Metagenomi Therapeutics make?
Metagenomi Therapeutics reported revenue of $25.21M for fiscal 2025, down 51.8% from a year earlier.
Does Metagenomi Therapeutics pay a dividend?
No. Metagenomi Therapeutics has not paid a cash dividend over the last twelve months.
When does Metagenomi Therapeutics report earnings next?
Metagenomi Therapeutics is expected to report Q4 FY2026 results on Mar 4, 2027, during market hours. The date is estimated from its past reporting pattern until the company confirms it.
How has MGX stock performed over the past year?
Including dividends, MGX returned -60.9% over the past year, against +11.3% for the S&P 500.
How many MGX shares are sold short?
1M shares were sold short at the latest FINRA report, 3.93% of the float, or 11.1 days of average trading volume.
Who are Metagenomi Therapeutics's competitors?
Companies most similar to Metagenomi Therapeutics by business, industry and size include SGMOQ, EDIT, CRSP, RLAY, DTIL.
See a number that looks wrong?